Cargando…
Targeting critical pathways in ferroptosis and enhancing antitumor therapy of Platinum drugs for colorectal cancer
Colorectal cancer (CRC) can be resistant to platinum drugs, possibly through ferroptosis suppression, albeit the need for further work to completely understand this mechanism. This work aimed to sum up current findings pertaining to oxaliplatin resistance (OR) or resistance to ascertain the potentia...
Autores principales: | Wang, Gang, Wang, Jun-Jie, Zhi-Min, Zhu, Xu, Xiao-Na, Shi, Feng, Fu, Xing-Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450309/ https://www.ncbi.nlm.nih.gov/pubmed/36718538 http://dx.doi.org/10.1177/00368504221147173 |
Ejemplares similares
-
The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents
por: Zhou, Jiabei, et al.
Publicado: (2020) -
Apolipoprotein L3 enhances CD8+ T cell antitumor immunity of colorectal cancer by promoting LDHA-mediated ferroptosis
por: Lv, Yang, et al.
Publicado: (2023) -
Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer
por: Chen, Siqi, et al.
Publicado: (2022) -
Structural Optimization of Platinum Drugs to Improve the Drug-Loading and Antitumor Efficacy of PLGA Nanoparticles
por: Sokol, Maria B., et al.
Publicado: (2022) -
Regulatory pathways and drugs associated with ferroptosis in tumors
por: Wang, Dan, et al.
Publicado: (2022)